The incidence of trisomy 8 as a sole chromosomal aberration in myeloid malignancies varies in relation to gender, age, prior iatrogenic genotoxic exposure, and morphology

被引:56
作者
Paulsson, K [1 ]
Säll, T
Fioretos, T
Mitelman, F
Johansson, B
机构
[1] Univ Lund Hosp, Dept Clin Genet, SE-22185 Lund, Sweden
[2] Lund Univ, Dept Genet, SE-22362 Lund, Sweden
关键词
D O I
10.1016/S0165-4608(01)00486-1
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Although trisomy 8 as a sole change is one of the most common chromosomal abnormalities in myeloid malignancies, it is largely unknown if the incidence of this aberration is influenced by other factors of clinical importance. In the present study, the frequencies of isolated +8 in relation to gender, age, previous treatment with chemo- or radiotherapy, and morphologic subtype were ascertained in published, as well as in our own unpublished, cases of acute myeloid leukemia (AML; n=4,246), myelodysplastic syndromes (MDS; n=1,817), and chronic myeloproliferative disorders (MPD; n=530). The frequencies of +8 were higher in MDS and MPD than in AML (7.5% vs. 5.6%; P <0.01) and varied among the morphologic subtypes of AML and MDS (P <0.001 and P <0.05, respectively). Trisomy 8 was more common in women than in men with MPD (11% vs. 5.1%; P <0.05). Furthermore, the frequencies of +8 were higher in de novo AML and MDS than in treatment-related cases (6.0% vs. 2.8%; P <0.01 and 8.6% vs. 1.5%; P <0.001, respectively). The incidence also varied significantly with age in AML (P <0.001), being more common in elderly patients. Although the causes for this frequency heterogeneity remain to be elucidated, possible explanations may include different environmental exposures affecting the origin of +8 in AML, MDS, and MPD and the presence of different underlying cryptic primary aberrations. (C) 2001 Elsevier Science Inc. All rights reserved.
引用
收藏
页码:160 / 165
页数:6
相关论文
共 32 条
[1]   Acute myeloid leukemia and clonal chromosome aberrations in relation to past exposure to organic solvents [J].
Albin, M ;
Björk, J ;
Welinder, H ;
Tinnerberg, H ;
Mauritzson, N ;
Johansson, B ;
Billström, R ;
Strömberg, U ;
Mikoczy, Z ;
Ahgren, T ;
Nilsson, PG ;
Mitelman, F ;
Hagmar, L .
SCANDINAVIAN JOURNAL OF WORK ENVIRONMENT & HEALTH, 2000, 26 (06) :482-491
[2]  
Andersen MK, 1998, HAEMATOLOGICA, V83, P483
[3]  
BENNETT JM, 1982, BRIT J HAEMATOL, V51, P189, DOI 10.1111/j.1365-2141.1982.tb08475.x
[4]   CRITERIA FOR THE DIAGNOSIS OF ACUTE-LEUKEMIA OF MEGAKARYOCYTE LINEAGE (M7) - A REPORT OF THE FRENCH-AMERICAN-BRITISH COOPERATIVE GROUP [J].
BENNETT, JM ;
CATOVSKY, D ;
DANIEL, MT ;
FLANDRIN, G ;
GALTON, DAG ;
GRALNICK, HR ;
SULTAN, C .
ANNALS OF INTERNAL MEDICINE, 1985, 103 (03) :460-462
[5]   PROPOSAL FOR THE RECOGNITION OF MINIMALLY DIFFERENTIATED ACUTE MYELOID-LEUKEMIA (AML-MO) [J].
BENNETT, JM ;
CATOVSKY, D ;
DANIEL, MT ;
FLANDRIN, G ;
GALTON, DAG ;
GRALNICK, HR ;
SULTAN, C .
BRITISH JOURNAL OF HAEMATOLOGY, 1991, 78 (03) :325-329
[6]   PROPOSED REVISED CRITERIA FOR THE CLASSIFICATION OF ACUTE MYELOID-LEUKEMIA - A REPORT OF THE FRENCH-AMERICAN-BRITISH COOPERATIVE GROUP [J].
BENNETT, JM ;
CATOVSKY, D ;
DANIEL, MT ;
FLANDRIN, G ;
GALTON, DAG ;
GRALNICK, HR ;
SULTAN, C .
ANNALS OF INTERNAL MEDICINE, 1985, 103 (04) :620-625
[7]   CYTOGENETIC STUDIES ON 519 CONSECUTIVE DENOVO ACUTE NONLYMPHOCYTIC LEUKEMIAS [J].
BERGER, R ;
FLANDRIN, G ;
BERNHEIM, A ;
LECONIAT, M ;
VECCHIONE, D ;
PACOT, A ;
DERRE, J ;
DANIEL, MT ;
VALENSI, F ;
SIGAUX, F ;
OCHOANOGUERA, ME .
CANCER GENETICS AND CYTOGENETICS, 1987, 29 (01) :9-21
[8]   Nineteen cases of the t(1;22)(p13;q13) acute megakaryoblastic leukaemia of infants/children and a review of 39 cases: report from a t(1;22) study group [J].
Bernstein, J ;
Dastugue, N ;
Haas, OA ;
Harbott, J ;
Heerema, NA ;
Huret, JL ;
Landman-Parker, J ;
LeBeau, MM ;
Leonard, C ;
Mann, G ;
Pages, MP ;
Perot, C ;
Pirc-Danoewinata, H ;
Roitzheim, B ;
Rubin, CM ;
Slociak, M ;
Viguie, F .
LEUKEMIA, 2000, 14 (01) :216-218
[9]  
Byrd JC, 1998, CLIN CANCER RES, V4, P1235
[10]  
Davico L, 1998, CANCER EPIDEM BIOMAR, V7, P1123